For research use only. Not for therapeutic Use.
Oral HDM2 inhibitor (or antagonist), which showed potent activity against multiple myeloma (MM) cells in vitro and ex vivo; potential agent to restore p53 function and to potentially impact other HDM2 dependent pathways.
Note: JNJ 26854165 dihydrochloride is a directly water-soluble form of JNJ 26854165 (Axon 1538)
KEYWORDS: JNJ26854165 dihydrochloride | Supplier | HDM2 inhibitor | Serdemetan dihydrochloride | JNJ26854165 | CAS [881202-16-0] | [881202-45-5] | p53 | HDM-MDM | Inhibitor | antagonist | multiple myeloma | MM | pathways
| Catalog Number | I047546 |
| CAS Number | 2109414-74-4 |
| Molecular Formula | C21H20N4.2HCl |
| Purity | ≥95% |
| Reference | T. Stühmer et al. A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo. J Clin Oncol 26: 2008, 26, 15S.
K Kojima et al. The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias. Mol. Cancer Ther. 2010, 9(9), 2545–2557. |
